PTC Therapeutics Inc. (PTCT)

26.23
NASDAQ : Health Technology
Prev Close 26.10
Day Low/High 25.60 / 26.46
52 Wk Low/High 10.65 / 33.22
Avg Volume 935.70K
Exchange NASDAQ
Shares Outstanding 45.80M
Market Cap 1.20B
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FIREFISH Transitions Into Pivotal Phase

FIREFISH Transitions Into Pivotal Phase

- First patient dosed in Type 1 Spinal Muscular Atrophy Program -

PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

- Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30, 2018

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

Notable Monday Option Activity: PTCT, OLN, ICPT

Notable Monday Option Activity: PTCT, OLN, ICPT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 46.8% of PTCT's average daily trading volume over the past month of 672,560 shares.

Notable Monday Option Activity: PTCT, DG, IDCC

Notable Monday Option Activity: PTCT, DG, IDCC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,631 contracts has been traded thus far today, a contract volume which is representative of approximately 663,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.2% of PTCT's average daily trading volume over the past month, of 882,305 shares.

Short Interest Increases 19% For PTCT

Short Interest Increases 19% For PTCT

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,353,958 share increase in total short interest for PTC Therapeutics Inc , to 8,436,994, an increase of 19.12% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 4,409 contracts has been traded thus far today, a contract volume which is representative of approximately 440,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 69.6% of PTCT's average daily trading volume over the past month, of 633,365 shares.

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $18.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $15 strike, which has a bid at the time of this writing of $2.80.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Short Interest In PTC Therapeutics Expands By 20.8%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,263,458 share increase in total short interest for PTC Therapeutics Inc , to 7,350,209, an increase of 20.76% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $12.40, changing hands for $12.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

TheStreet Quant Rating: D (Sell)